Статья

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Marilyn S. AlbertDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USASteven T. DeKoskyDepartment of Neurology University of Virginia Charlottesville VA USADennis W. DicksonDepartment of Pathology Mayo Clinic Jacksonville FL USABruno DuboisInstitute for Memory and Alzheimer's Disease, INSERM Unit Cognition, Neuro‐imagerie et maladies due Cerveau, Groupe Hospitalier Pitie‐Salpetriere Paris FranceHoward FeldmanBristol‐Myers Squibb Neuroscience Wallingford CT USANick C. FoxInstitute of Neurology, University College London London United KingdomAnthony GamstDepartment of Neuroscience University of California San Diego CA USADavid M. HoltzmanDepartment of Neurology Washington University St. Louis MO USAWilliam J. JagustHelen Wills Neuroscience Institute, University of California Berkeley CA USARonald C. PetersenDepartment of Neurology Mayo Clinic Rochester MN USAPeter J. SnyderDepartment of Neurology Alpert Medical School of Brown University Providence RI USAMaría C. CarrilloAlzheimer's Association Chicago IL USABill ThiesAlzheimer's Association Chicago IL USACreighton H. PhelpsNational Institute on Aging Bethesda MD USA

2011en

ABI

Аннотация

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

Перевод пока недоступен

Идентификаторы

DOI: 10.1016/j.jalz.2011.03.008

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar